Bicara Therapeutics Inc. (BCAX) Financial Statements
Free cash flow over the same period: -$135.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BCAXBicara Therapeutics Inc.Follow BCAX — free
—
Price chart with a free account
- Market cap
- 1.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 63.6 | — | — | |
| Operating income | -82.4 | -155.6 | -202.0 | |
| Pre-tax income | -67.8 | -137.7 | -185.2 | |
| Income tax | 0.2 | 0.2 | 0.2 | |
| Net income | -68.0 | -138.0 | -185.4 | |
| Diluted EPS ($) | -4.05 | -2.52 | -2.74 | |
| Diluted shares (mn) | 16.8 | 54.7 | — |
USD millions · SEC XBRL
Bicara Therapeutics Inc. — questions
- What is Bicara Therapeutics Inc.'s net income?
- -$185.4M over the twelve months to 2026-06-30.
- What is Bicara Therapeutics Inc.'s free cash flow?
- -$135.2M over the twelve months to 2026-06-30.
- What are Bicara Therapeutics Inc.'s diluted earnings per share?
- $-2.74 over the twelve months to 2026-06-30.
Every figure on this page comes from Bicara Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.